undamentalytics Newsletter
Sign in

Beam Therapeutics Inc. cash flow statement

In fiscal 2025, Beam Therapeutics Inc.'s operations generated −$345m of cash; it spent $14.9m on capital projects, leaving free cash flow of −$360m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Cash from operations−72−96−6623−149−347−345−389
Depreciation and amortisation4571420222222
Stock-based pay7154484991219477
Capital spending131647493491510
Free cash flow−85−112−113−26−183−356−360−398
Free cash flow after stock pay−92−127−157−111−282−477−454−476
Shares issued——757108237———

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: BEAM vs KPTIAGEN vs BEAMBEAM vs IBRXBEAM vs NUVB

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Beam Therapeutics Inc.'s SEC filings (10-K and 10-Q), retrieved November 3, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Beam Therapeutics Inc.